The Next Drugs: The Future for Biosimilars
An Atlantic Policy Briefing

March 15, 2017
Washington, DC

New guidelines on naming and interchangeability from the Food and Drug Administration point to a changing role for biosimilars, while some of the Trump Administration's policy priorities, if implemented, could alter the dimensions of the American market.

Join The Atlantic as we gather key stakeholders to examine the future for biosimilars domestically and abroad. What impact will the President's policies have on the industry? Will changes in regulation affect how many biosimilars are approved, and what impact will these have on ensuring that these drugs are safe and accessible for the patients who need them?

8:00 am — Guest Arrival and Networking Breakfast
8:30 am — Program Begins
10:00 am — Program Concludes

Knight Broadcast Studio
555 Pennsylvania Avenue, NW
Washington, DC 20001


For more information, please contact Carly Spraggins at

Presented by

Atlantic Live


Also in This Series

Upcoming Events